These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 20467346)

  • 1. A prospective trial on the effect of body mass index and sex on plasma octreotide levels in patients undergoing long-term octreotide LAR therapy.
    Joseph S; Li G; Lindholm E; Zhou Y; Go VL; Vinik AI; O'Dorisio TM; Mamikunian G; Woltering EA
    Pancreas; 2010 Oct; 39(7):964-6. PubMed ID: 20467346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of octreotide LAR dose and weight on octreotide blood levels in patients with neuroendocrine tumors.
    Woltering EA; Mamikunian PM; Zietz S; Krutzik SR; Go VL; Vinik AI; Vinik E; O'Dorisio TM; Mamikunian G
    Pancreas; 2005 Nov; 31(4):392-400. PubMed ID: 16258376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical value of monitoring plasma octreotide levels during chronic octreotide long-acting repeatable therapy in carcinoid patients.
    Woltering EA; Salvo VA; O'Dorisio TM; Lyons J; Li G; Zhou Y; Seward JR; Go VL; Vinik AI; Mamikunian P; Mamikunian G
    Pancreas; 2008 Jul; 37(1):94-100. PubMed ID: 18580450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review.
    Broder MS; Beenhouwer D; Strosberg JR; Neary MP; Cherepanov D
    World J Gastroenterol; 2015 Feb; 21(6):1945-55. PubMed ID: 25684964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical management of neuroendocrine tumors with long-acting repeatable (LAR) octreotide: comparison with standard subcutaneous octreotide therapy.
    Dogliotti L; Tampellini M; Stivanello M; Gorzegno G; Fabiani L
    Ann Oncol; 2001; 12 Suppl 2():S105-9. PubMed ID: 11762334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of dose escalation of octreotide long-acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors.
    Al-Efraij K; Aljama MA; Kennecke HF
    Cancer Med; 2015 Jun; 4(6):864-70. PubMed ID: 25727756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of octreotide long acting repeatable (LAR) as second-line therapy in advanced neuroendocrine tumors in different clinical settings: an Italian Delphi survey.
    Falconi M; Fazio N; Ferone D; Versari A
    Expert Opin Pharmacother; 2020 Dec; 21(18):2317-2324. PubMed ID: 32990061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Octreotide long-acting repeatable among elderly patients with neuroendocrine tumors: a survival analysis of SEER-Medicare data.
    Shen C; Shih YC; Xu Y; Yao JC
    Cancer Epidemiol Biomarkers Prev; 2015 Nov; 24(11):1656-65. PubMed ID: 26315553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Octreotide long-acting repeatable use among elderly patients with carcinoid syndrome and survival outcomes: a population-based analysis.
    Shen C; Shih YC; Xu Y; Yao JC
    Cancer; 2014 Jul; 120(13):2039-49. PubMed ID: 24676892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose octreotide acetate for management of gastroenteropancreatic neuroendocrine tumors.
    Chadha MK; Lombardo J; Mashtare T; Wilding GE; Litwin A; Raczyk C; Gibbs JF; Kuvshinoff B; Javle MM; Iyer RV
    Anticancer Res; 2009 Oct; 29(10):4127-30. PubMed ID: 19846960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved survival with higher doses of octreotide long-acting release in gastroenteropancreatic neuroendocrine tumors.
    Lau SC; Abdel-Rahman O; Cheung WY
    Med Oncol; 2018 Aug; 35(9):123. PubMed ID: 30078166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Octreotide LAR Dosage and Survival Among Elderly Patients With Distant-Stage Neuroendocrine Tumors.
    Shen C; Xu Y; Dasari A; Shih YC; Yao JC
    Oncologist; 2016 Mar; 21(3):308-13. PubMed ID: 26911407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prescribing Characteristics of Octreotide Immediate-Release and Long-Acting Release in Patients with Neuroendocrine Tumors.
    Cheng Y; Anthony L; Delcher C; Moga DC; Chauhan A; Huang B; Adams V
    Oncologist; 2023 Jun; 28(6):479-485. PubMed ID: 36994847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis.
    Strosberg JR; Yao JC; Bajetta E; Aout M; Bakker B; Hainsworth JD; Ruszniewski PB; Van Cutsem E; Öberg K; Pavel ME
    Endocr Relat Cancer; 2015 Dec; 22(6):933-40. PubMed ID: 26373569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study.
    Fazio N; Granberg D; Grossman A; Saletan S; Klimovsky J; Panneerselvam A; Wolin EM
    Chest; 2013 Apr; 143(4):955-962. PubMed ID: 23187897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose escalation of octreotide LAR is safe and effective in patients with advanced gastrointestinal neuroendocrine tumours for control of symptoms and tumor progression.
    Verslype C
    Acta Gastroenterol Belg; 2011 Mar; 74(1):93-4. PubMed ID: 21563661
    [No Abstract]   [Full Text] [Related]  

  • 17. Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses.
    Ferolla P; Faggiano A; Grimaldi F; Ferone D; Scarpelli G; Ramundo V; Severino R; Bellucci MC; Camera LM; Lombardi G; Angeletti G; Colao A
    J Endocrinol Invest; 2012 Mar; 35(3):326-31. PubMed ID: 21757992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival.
    Rinke A; Wittenberg M; Schade-Brittinger C; Aminossadati B; Ronicke E; Gress TM; Müller HH; Arnold R;
    Neuroendocrinology; 2017; 104(1):26-32. PubMed ID: 26731483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.
    Rinke A; Müller HH; Schade-Brittinger C; Klose KJ; Barth P; Wied M; Mayer C; Aminossadati B; Pape UF; Bläker M; Harder J; Arnold C; Gress T; Arnold R;
    J Clin Oncol; 2009 Oct; 27(28):4656-63. PubMed ID: 19704057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR.
    Jenkins PJ; Emery M; Howling SJ; Evanson J; Besser GM; Monson JP
    Horm Res; 2004; 62(5):227-32. PubMed ID: 15477693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.